FIELD: medicine.
SUBSTANCE: group of inventions relates to selection of a suitable anti-cancer medication for treating lung cancer, prediction of the lung tumour response to treatment with the anti-cancer medication, as well as to application of a matrix for selection of the suitable anti-cancer medication for lung cancer treatment. The group of inventions is based on detection of activation states of components of signal transduction pathways in cancer cells, including Her3 (ErbB3).
EFFECT: group of inventions assists a doctor in selection of a suitable anti-tumour therapy in a proper dose and in proper time for each patient.
12 cl, 5 dwg, 22 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF DETECTING ONCOGENIC FUSED PROTEINS, BASED ON ANALYSIS OF CLOSE MUTUAL LOCATION | 2010 |
|
RU2558797C2 |
| DEVICE AND METHOD FOR LEUKOCYTE AND CANCER CELL RECOVERY BY FILTRATION | 2012 |
|
RU2578848C2 |
| METHOD OF TREATING GEFITINIB-RESISTANT CANCER | 2006 |
|
RU2405566C9 |
| THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR BLADDER CANCER | 2015 |
|
RU2739942C2 |
| METHODS OF PREDICTING RESPONSE OF TRIPLE NEGATIVE MAMMARY GLAND CANCER TO THERAPY | 2011 |
|
RU2558931C2 |
| COMPOSITIONS AND METHODS OF TREATING AND DIAGNOSING CANCER-RESISTANT CANCER | 2015 |
|
RU2710735C2 |
| COMBINED C-MET AND EGFR ANTAGONISTS THERAPY | 2009 |
|
RU2601892C2 |
| TREATING LUNG CANCER BY COMBINATION OF ANTI-PD-1 AND OTHER ANTI-CANCER AGENTS | 2015 |
|
RU2695332C2 |
| NEUREGULIN ANTAGONISTS AND USE THEREOF IN TREATING MALIGNANT GROWTH | 2011 |
|
RU2587619C2 |
| BISPECIFIC ANTIBODIES TO CD25 AND Fc GAMMA-RECEPTOR FOR ELIMINATION OF TUMOR-SPECIFIC CELLS | 2017 |
|
RU2759970C2 |
